Sivi Ouwerkerk‐Mahadevan

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

Eric Lawitz, Mark Sulkowski, Reem Ghalib et al. · The Lancet · 2014 · 818 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

Ira M. Jacobson, Gregory J. Dore, Graham R. Foster et al. · The Lancet · 2014 · 436 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

Michael P. Manns, Patrick Marcellin, Fred Poordad et al. · The Lancet · 2014 · 375 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial

Xavier Forns, Eric Lawitz, Stefan Zeuzem et al. · Gastroenterology · 2014 · 256 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

1413 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-2, A PHASE III TRIAL

M.P. Manns, Patrick Marcellin, Fred Poordad et al. · Journal of Hepatology · 2013 · 122 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +12